Made-In-Singapore Active Pharmaceutical Ingredients Gets Easier Access to EU with Recognition by European Commission
18 November 2026
Audiences
Consumer
Healthcare professional
Industry member
Product-type
Medical devices
Therapeutic Products
Singapore, through the Health Sciences Authority (HSA) has been recognised by the European Commission for its regulatory framework for active pharmaceutical ingredients (APIs), affirming that its quality oversight of APIs produced in Singapore provides public health protection equivalent to that required in the European Union (EU). The Commission has adopted a decision on 15 November 2026 that Singapore’s standards and controls on Good Manufacturing Practice (GMP) in Singapore for APIs, which are the active substances responsible for the intended therapeutic effects of medicines, is equivalent to that in the EU.
2 With this recognition, made-in-Singapore APIs for use in human medicines can now be exported to the EU through simpler and faster procedures, without the usual written confirmation from HSA on GMP standards and manufacturing site oversight. API manufacturers can expect simpler processes, while patients can be assured of continued stringent quality standards from Singapore.
3 Singapore joins a select group of countries including the United States, Japan, Australia, Switzerland, South Korea, Canada, Brazil and Israel that have achieved this recognition. The Commission’s decision follows HSA's implementation of a strengthened regulatory framework for APIs in December 2023 and the Commission’s assessment of HSA’s framework, including an on-site review in March 2026.
Deepening Regulatory Cooperation with European Partners
4 HSA has also signed a Working Arrangement with the Commission’s Directorate-General Health and Food Safety (DG SANTE) and European Medicines Agency (EMA) on 10 November 2026 to strengthen scientific and regulatory cooperation on medicines and medical devices. The Arrangement provides a structured framework for information sharing, scientific and expert exchanges, and opportunities to explore collaborative regulatory reviews. This Arrangement also envisages possible observer or expert participation in scientific committees and initiatives such as through EMA's Opening Procedures to Non-EU Authorities (OPEN) framework.
5 This closer cooperation will enable regulators to share expertise and leverage one another's scientific assessments, supporting more informed and timely regulatory decisions. It aims to enhance regulatory efficiency thereby facilitating patients' access to safe, effective and quality medicines and medical devices.
6 Adjunct Professor (Dr) Raymond Chua, Chief Executive Officer of HSA, said: “The European Commission's recognition of Singapore's regulatory standards is a strong affirmation of the trust placed in our regulatory system underpinning our pharmaceutical manufacturing sector. It reduces unnecessary administrative requirements for Singapore-made ingredients entering the EU while maintaining rigorous safeguards for patients. Together with our new Working Arrangement with the European Commission’s Directorate-General for Health & Food Safety (DG SANTE) and European Medicines Agency, it strengthens the trust and connectivity between our regulatory systems. By sharing scientific expertise and exploring closer collaboration, we can support regulatory efficiency, responsible innovation and timely patient access to safe and effective health products. Strong regulations should not only protect public health but also help good innovations reach those who need them.”
7 Ms Poh Hwee Tee, Singapore Association of Pharmaceutical Industries' (SAPI) President, said: “SAPI welcomes the European Commission’s recognition of Singapore’s API regulatory framework, which reflects the high standards of our regulatory system and strengthens regulatory cooperation between Singapore and the EU. By simplifying export requirements for Singapore-manufactured APIs, this recognition is a positive step towards reducing regulatory burden and facilitating international trade. It also reinforces Singapore’s reputation as a trusted and high-quality pharmaceutical manufacturing hub, contributing to the strength of our broader pharmaceutical ecosystem.”
HEALTH SCIENCES AUTHORITY
SINGAPORE
18 NOVEMBER 2026
ANNEX
Singapore Recognised by the European Commission for Its Regulatory Framework for Active Pharmaceutical Ingredients

Adjunct Professor (Dr) Raymond Chua presenting a thank-you note to Ms Lenita Lindström, Senior Expert, Directorate-General for Health and Food Safety, European Commission
Signing of Working Arrangement between Health Sciences Authority, Singapore, the European Commission’s Directorate-General Health and Food Safety (DG SANTE) and European Medicines Agency (EMA)
The Working Arrangement was signed by all three parties, with DG SANTE signing after EMA and HSA.

From left: Ms Emer Cooke, Executive Director, European Medicines Agency and Adjunct Professor (Dr) Raymond Chua, Chief Executive Officer, HSA, Singapore
All photos are to be credited to the Health Sciences Authority, Singapore.
Subscribe (opens in new tab) to stay up to date with HSA news and regulatory updates.
